The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes. Dexcom's shares fell nearly 37% ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

As Dexcom seeks expanded coverage of its continuous glucose monitors (CGM) for people with Type 2 diabetes, it expects its Stelo users will shift. “What we hope for is that we can get insurance ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

That included stats showing Dexcom ... the FDA. Stelo’s features will also migrate to other systems, with the over-the-counter wearable acting as a gateway for people new to CGM as a whole.

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...